GLOW peptide blend: claims, evidence, and dose context

GLOW combines three peptides in a single supplier-labeled 70 mg vial: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500. The blend is promoted for skin quality and tissue recovery. Its name and ingredient total do not establish a treatment effect or individual dose. [1]

What is the rationale?

GHK-Cu is a copper-binding peptide studied for skin and wound biology. BPC-157 has mostly animal and cell repair research. Thymosin beta-4 has been studied in topical wound settings, while TB-500 product naming can refer to a different fragment. These separate findings do not show that a GLOW injection heals a tendon, improves scarring, or builds collagen in living people. [2,3]

What has been tested for the exact blend?

We did not identify a controlled human trial of the three-component GLOW formulation. A fixed combination has its own questions about ingredient identity, interaction, stability, and safety. Even if each component has a plausible mechanism, a clinical claim for the mixture requires direct testing. [1–3]

What are the safety limits?

FDA flags potential immune-reaction and impurity concerns for several research peptides, including BPC-157 and TB-500-related substances. Injection-site reactions can also occur. Because GLOW fixes all three ingredients in a 5:1:1 ratio, raising one component necessarily raises exposure to the other two. A supplier label does not independently confirm sterility or delivered amounts. [1,3]